Markets

Alton Sells 15000 Shares of Gilead Sciences, Inc. (GILD) Stock

Alton Sells 15000 Shares of Gilead Sciences, Inc. (GILD) Stock

Gilead Sciences Inc now has $93.62 billion valuation. The stock declined 0.30% or $0.22 reaching $72.22 on the news.

Gilead Sciences Inc. (GILD) is expected to post revenue of $5.69 Billion in the current quarter, according to consensus of 19 analysts. It has underperformed by 25.06% the S&P500.

Wilen Investment Management Corp decreased Harris Corp.

David Atterbury decreased its stake in Pros Holdings Inc (PRO) by 3.67% based on its latest 2017Q2 regulatory filing with the SEC. About 2.29M shares traded. The YTD performance of the stock stands at 1.16 Percent. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company's stock worth $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Capstead Mtg Corp now has $853.41 million valuation. The stock declined 0.89% or $0.65 reaching $71.79 on the news. Capstead Mortgage Corporation (NYSE:CMO) has risen 6.72% since November 19, 2016 and is uptrending.

Analysts await Metlife Inc (NYSE:MET) to report earnings on February, 7. They expect $1.40 earnings per share, down 1.41% or $0.02 from last year's $1.42 per share. MET's profit will be $1.18B for 11.53 P/E if the $1.12 EPS becomes a reality. The company's quarterly EPS surprised Wall Street by as much as 7% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

Investors sentiment increased to 1.02 in Q2 2017. Its down 0.38, from 1.51 in 2017Q1. 43 funds opened positions while 127 raised stakes. Capstone Asset Mngmt invested in 26,670 shares or 0.01% of the stock. Interest Limited Ca invested in 0.75% or 159,607 shares. Barclays Public Ltd Com reported 0% stake. 272 were accumulated by First Manhattan. Chesley Taft And Assoc Ltd Com invested in 3,160 shares. The hedge fund held 38,600 shares of the company at the end of 2017Q2, valued at $631,000, down from 60,000 at the end of the previous reported quarter. Kentucky Retirement owns 83,767 shares.




Exelon Corporation (NYSE:EXC) shares were trading higher by 0.05 percent ($0.02) at $41.26 a piece in Sunday's session. First National Bank & Trust Of Mount Dora Inv Svcs invested in 3.03% or 53,510 shares. (NASDAQ:GILD). Comml Bank Of Hawaii holds 0.21% of its portfolio in Gilead Sciences, Inc. Moreover, Roffman Miller Associates Incorporated Pa has 0.03% invested in UnitedHealth Group Inc (NYSE:UNH).

Since June 1, 2017, it had 0 buys, and 2 sales for $5.11 million activity. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. Therefore 71% are positive. Harris had 31 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned "Outperform" rating on Tuesday, September 20 by Wedbush.

In related news, CFO Robin L. Washington sold 51,820 shares of the company's stock in a transaction dated Thursday, September 7th. RBC Capital Markets maintained the stock with "Outperform" rating in Wednesday, February 3 report. The rating was maintained by Jefferies with "Buy" on Friday, September 22. Standpoint Research has "Buy" rating and $110 target. The rating was initiated by Oppenheimer on Wednesday, October 4 with "Hold". The company now has a consensus rating of "Buy" and a consensus price target of $84.87. The firm earned "Outperform" rating on Wednesday, July 20 by RBC Capital Markets. MARTIN JOHN C sold $4.78 million worth of Gilead Sciences, Inc. (NASDAQ:GILD). Counselors reported 12,080 shares. (Call) (GILD) by 100% based on its latest 2017Q2 regulatory filing with the SEC. Investment Centers of America Inc. grew its stake in Gilead Sciences by 7.2% in the first quarter. Reilly Advsrs Ltd Liability Company holds 0.01% of its portfolio in Gilead Sciences, Inc. Therefore 67% are positive. Grupo Aeroportuario del Sureste had 6 analyst reports since August 25, 2015 according to SRatingsIntel. Moreover, Pillar Pacific Mgmt Lc has 1.01% invested in Gilead Sciences, Inc. Eleven research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company's stock. The firm has "Hold" rating by Keefe Bruyette & Woods given on Friday, October 27. The company was initiated on Friday, February 5 by Leerink Swann. JMP Securities maintained Ares Capital Corporation (NASDAQ:ARCC) rating on Tuesday, August 9. The company was upgraded on Thursday, October 1 by Macquarie Research. The firm has "Hold" rating by Stifel Nicolaus given on Friday, January 15. The stock has "Hold" rating by Maxim Group on Tuesday, May 30. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share. Its up 0.02, from 0.91 in 2017Q1.

Other institutional investors also recently bought and sold shares of the company. Raises Position in Gilead Sciences, Inc. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.14. Of the analysts surveyed by Reuters that track Gilead Sciences, Inc. Horan Capital Management has invested 4.33% in Gilead Sciences, Inc. Cap Va invested in 126,828 shares or 2.68% of the stock. Morgan Dempsey Capital reported 338,375 shares. Evercore Wealth Mngmt Llc holds 0.16% or 58,727 shares in its portfolio. Fdx Advsr reported 32,521 shares stake. 505,760 are held by Fmr Ltd Company. Redburn Partners began coverage on Gilead Sciences in a research report on Wednesday, July 26th. Commercial Bank Hapoalim Bm holds 0.52% or 30,772 shares. Mckinley Capital Ltd Limited Liability Company Delaware has invested 0.03% of its portfolio in Capstead Mortgage Corporation (NYSE:CMO). Fagan Associates Inc. grew its stake in Gilead Sciences by 2.6% in the second quarter. (NASDAQ:GILD) for 2.61 million shares. 20,617 were accumulated by Regent Investment. Wolverine Asset Management Limited invested in 1.14 million shares. Alps stated it has 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 12,192 shares.

Since June 1, 2017, it had 0 insider buys, and 2 selling transactions for $5.11 million activity. Also, EVP Gregg H. Alton sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, November 1st. The stock of Gilead Sciences, Inc.